Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
I004
Amphastar France Pharmaceuticals
Pharmacokinetics
2 trials -
IM JZP-458
Jazz Pharmaceuticals Ireland Limited
Acute Lymphoblastic Leukemia
1 trial -
IMBRUVICA 140 mg hard capsules, Calquence 100 mg film-coated tablets, Calquence 100 mg hard capsules, IMBRUVICA 140 mg hard capsules
Lacuna Pharma Pty Ltd
High Risk Chronic Lymphocytic Leukaemia
1 trial -
IMIPENEM, CILASTATIN AND RELEBACTAM, AMIKACIN , TIGECYCLINE , Nacubactam, AZACTAM 1 g, poudre et solution pour usage parentéral, COLISTIN , Cefepime Panpharma, 2 g, proszek do sporządzania roztworu do wstrzykiwań lub infuzji
Lacuna Pharma Pty Ltd
Complicated urinary tract infection (cUTI), acute uncomplicated pyelonephritis (AP), hospital acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), and complicated intra-abdominal infection (cIAI)
1 trial -
IMUKIN 2 X 106 UI (0,1 mg), solution injectable, SODIUM CHLORIDE
Pari Pharma GmbH
Post-aggressive immunosuppression
1 trial -
INCA33890, Placebo contains the same formulation buffer, 10 mM acetate, 9% (w/v) sucrose and 0.02% (w/v) polysorbate 80, at pH 5.5, without the active pharmaceutical ingredient., CALCIUM FOLINATE, BEVACIZUMAB, OXALIPLATIN, FLUOROURACIL
Incyte
Metastatic Microsatellite Stable Colorectal Cancer
1 trial -
INCLISIRAN, -
Novartis Pharmaceuticals
Familial hypercholsterolemia
1 trial -
INCLISIRAN, KJX839, Placebo to KJX839 (Inclisiran) 0 mg/1.5 mL Solution for injection in vial
Novartis Pharmaceuticals
Heterozygous Familial Hypercholesterolemia
1 trial -
INCLISIRAN, KJX839, Placebo to KJX839 (Inclisiran) 0 mg/1.5 mL Solution for injection in vial
Novartis Pharmaceuticals
homozygous familial hypercholesterolemia
1 trial -
INEBILIZUMAB, 10 mL (nominal) solution containing 10 mM histidine/histidine hydrochloride, 75 mM sodium chloride, 106 mM (4% [w/v]) trehalose dihydrate, and 0.02% (w/v) polysorbate 80, pH 6.0
Elan Pharma International
Myasthenia Gravis which is either due to acetylcholine receptor antibodies (AChR) or muscle specific kinase antibodies (MuSK).
1 trial -
INEBILIZUMAB, 10 mL (nominal) solution containing 20 mM histidine/histidine hydrochloride, 70 mM sodium chloride, 106 mM (4% [w/v]) trehalose dihydrate, and 0.01% (w/v) polysorbate 80
Elan Pharma International
Immunoglobulin G4-related disease (IgG4-RD)
1 trial -
INO-4800
INOVIO PHARMACEUTICALS, INC.
Coronavirus Infection
4 trials -
INZ-701
BioMarin Pharmaceutical Australia Pty Ltd
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency
2 trials -
INZ-701
Lacuna Pharma Pty Ltd
Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency
1 trial -
INZ-701, INZ-701
Lacuna Pharma Pty Ltd
Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency
1 trial -
ION 682884, ION 682884
IONIS PHARMACEUTICALS INC
Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
1 trial -
ION 682884, Placebo injection, 0.8 ml (is a sterile, preservative-free, parenteral solution of sodium chloride and riboflavin in Water for Injection) for subcutaneous administration
IONIS PHARMACEUTICALS INC
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
1 trial -
ION363
IONIS PHARMACEUTICALS INC
Amyotrophic Lateral Sclerosis
1 trial -
ION363, ION363, Artificial Cerebrospinal Fluid (aCSF) for Injection, 5.0 mL (Placebo)
IONIS PHARMACEUTICALS INC
Amyotrophic Lateral Sclerosis with Fused in Sarcoma mutations
1 trial -
ION582
IONIS PHARMACEUTICALS INC
Angelman syndrome
1 trial -
ION582
IONIS PHARMACEUTICALS INC
Angelman Syndrome
2 trials -
IPTACOPAN
Novartis Pharmaceuticals
Atypical hemolytic uremic syndrome
1 trial -
IPTACOPAN
Novartis Pharmaceuticals
Atypical Hemolytic Uremic Syndrome (aHUS)
1 trial -
IPTACOPAN
Novartis Pharmaceuticals
Atypical Hemolytic Uremic Syndrome (aHUS)
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources